Sinclair Pharmaceuticals receives FDA approval for Gelclair in U.S.

Jan. 22, 2002
Gelclair, a novel approach to managing painful oral conditions, has received FDA approval in U.S.

Sinclair Pharmaceuticals annouces that Gelclair, their novel product for the management of oral mucositis, has gained 510K (Medical Device) approval from the U.S. Food & Drug Administration.
Mucositis is a painful ulcerative and inflammatory condition affecting the mouth. It is seen alongside many chemotheraphy regimens and radiotherapy to the head and neck. The pain of mucositis often prevents the patient from eating or drinking and so can result in the need to reduce a patient's treatment. Approximately 40% of all patients receiving chemotherapy in the U.S. experience mucositis, and an effective solution to the problem is in demand by the medical profession.
For more information, visit